

# Accreditation Information

This activity is jointly provided by  and .

Support for this accredited continuing education activity has been made possible through an educational grant from Incyte.

## Activity Description

This educational activity is targeted to Advanced Practice Providers (APPs) – Physician Assistants and Nurse Practitioners and is designed to be responsive, interactive, and highly practical. This presentation will provide APPs with a comprehensive overview of vitiligo, emphasizing pathogenic mechanisms, patient burden, and emerging treatment approaches. From this foundational knowledge base, the expert faculty will then guide attendees through an interactive, dynamic, case-based segment to ensure the real-world clinical translatability of principles learned during the session.

## Activity Faculty

Shanna Miranti, MPAS, PA-C  
Riverside Dermatology  
Naples, Florida



## Target Audience

This activity has been designed to meet the educational needs of Advanced Practice Providers (APPs) – Physician Assistants and Nurse Practitioners – who practice in community settings. Other healthcare providers may also participate.

## Learning Objectives

After participating in the activity, learners should be better able to

- Appraise the clinical presentation and diagnosis of vitiligo, including the fundamental role of autoimmune response and potential triggers.
- Describe the significant, multifaceted impact of vitiligo on patient quality of life, with emphasis on both cosmetic and non-cosmetic manifestations.
- Evaluate the pathophysiologic autoimmune mechanisms driving vitiligo pathogenesis and progression, with a focus on the functional loss of melanocytes.
- Explore and characterize the JAK signaling pathway as a prominent therapeutic target in the treatment of vitiligo.
- Review historical vitiligo treatment approaches and identify clinical gaps and unmet patient needs.
- Examine the expanding treatment armamentarium for patients with vitiligo, with an expert deep dive into a newly approved topical treatment and recent advancements in understanding the potential impact of lifestyle modification as a management strategy.
- Design individualized treatment strategies for patients with vitiligo, highlighting recent clinical trial findings of newer, emerging therapeutics and their placement in the evolving treatment calculus.

# Accreditation Information

## Accreditation and Credit Designation



In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Physician Assistants

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 hour(s) of AAPA Category I CME credits. Physician assistants should claim only those hours actually spent participating in the CME activity.

### Nurse Practitioners and Nurses

American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours (0.60 pharmacotherapeutic contact hours).

### Other HCPs:

Other members of the care team will receive a certificate of participation.

## Disclosures

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships with ineligible companies are as follows:

### *Faculty Educator*

Shanna Miranti, MPAS, PA-C

Advisory Board: Almirall, Arcutis Biotherapeutics, Dermavant Sciences, EPI Health, Galderma, Incyte, Ortho Dermatologics, Verrica Pharmaceuticals

Consultant: Galderma, Incyte, Ortho Dermatologics, Saorsa, Verrica Pharmaceuticals

Board Member: Diversity in Dermatology, *Dermatology Times*, *JCAD-NPPA*

Speakers Bureau: Almirall, Galderma, EPI Health, Incyte, Journey Medical, Ortho Dermatologics, Verrica Pharmaceuticals

### *Independent Clinical Reviewer*

Ashley Ellis, PharmD, MBA, CDECS has no financial disclosures with ineligible companies to report.

### *Planning Committee*

No members of the planning committee from the Academy or Cornerstone has financial relationships to disclose with ineligible companies.

# Accreditation Information

This activity will not review off-label or investigational information.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Cornerstone Medical Education. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

## Privacy

For more information about the American Academy of CME privacy policy, please access <http://www.academycme.org/privacy.htm>

## Copyright

© 2024. This accredited continuing education activity is held as copyrighted © by American Academy of CME and Cornerstone Medical Education. Through this notice, the Academy and Cornerstone grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

## Contact

For any questions, please contact: [CEServices@academycme.org](mailto:CEServices@academycme.org)